- 34 Downloads
An effective boosting of the host immunocompetence is possible through synthetic immunomodulators, keeping in mind that they are no panacea for all microbial diseases. No drug is effective on all phases or effector cells of the immune response and it is postulated that in a near future combined therapies will be attempted with antibiotics or anti-cancer agents.
KeywordsImmune Response Effector Cell Combine Therapy Host Immunocompetence Microbial Disease
Unable to display preview. Download preview PDF.
- 1.Fenichel RL and Chirigos MA Eds. Immune modulation agents and their mechanisms. Marcel Dekker, New York, 1984.Google Scholar
- 2.Laurie J, Moertel C, Fleming T, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and Mayo Clinic. J. Clin. Oncol. 1989; 7:1447–1456.Google Scholar
- 3.Langtry HD and Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1989; 37:408–50.Google Scholar
- 4.Pedersen C, Sandstrom E, Petersen CS et al. The efficacy of inosine pranobex in preventing the Acquired Immunodeficiency Syndrome in patients with Human Immunodeficiency virus infection.N Engl J Med 1990; 322: 1757–63.Google Scholar
- 5.DeSimone C, Albertini F, Almaviva M et al. Clinical and Immunological assessment in HIV + subjects receiving Inosine-Pranobex: a Randomized, Multicentric study; Med Oncol. and Tumor Pharmacother. 1989; 6: 63–67.Google Scholar
- 6.DeSimone C, Tzantzoglou S, Vullo V et al. Inosine pranobex and zidovudine metabolism. Lancet 1989; 2:977.Google Scholar
- 7.De Simone C, Foresta P and Arrigoni Martelli E Eds. ST789: chemical and immunopharmacological profile. Thymus. 1991, in press.Google Scholar